News Posts List

Georgia Bio Names Mountain View High School Junior as Georgia BioGENEius Winner


Suraj Modi Advances to Boston to International Competition Against Top Students Atlanta, GA (April 6, 2018) – Georgia Bio and the Georgia BioEd Institute today named Suraj Modi, Mountain View High School junior of Lawrenceville, GA, as the winner of the 2018 Georgia BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field. As Georgia’s BioGENEius finalist, Suraj will attend the 2018 BIO International Convention, the industry’s trade conference from June 3-6 in Boston, MA, where he will engage with leading companies, scientists and innovators currently transforming the scientific landscape in order to gain valuable insights into an industry making significant contributions to the world. While in Boston, Suraj will compete against high school students from the U.S., Canada and Germany in the International BioGENEius Challenge. The student projects will represent a range of biotechnology topics such as healthcare, agriculture, and the environment.

Intent Solutions™ Hires Chief Technology Officer


ATLANTA (March 15, 2018) – Intent Solutions™, creator of the breakthrough medical device technology TAD™, is excited to announce the addition of its new Chief Technology Officer, John Kidd. An accomplished technology executive with experience including researching, developing, and implementing technology solutions deployed at multiple Fortune 100 companies, Kidd has a proven track record in developing enterprise software applications for startup and high-growth companies that benefit the businesses bottom-line while addressing customer needs. TAD, for “Take As Directed,” is a smart, mobile, medication dispenser that assists patients in obtaining better health outcomes by helping the right patient take the right dose at the right time.

MiMedx Announces Expectation to Exceed the $92 Million


MiMedx Announces Expectation to Exceed the $92 Million Top End of First Quarter Revenue Guidance MARIETTA, Ga., March 15, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced its expectation for first quarter of 2018 revenue to exceed the $92 million high end of its previously released guidance. MiMedx reiterated its full-year 2018 revenue guidance range of $383 million to $387 million. Parker H. "Pete" Petit, Chairman and CEO, commented, "This year started off strong, and we have continued to see momentum build through the quarter. With our current revenue pace and more than two-thirds of the first quarter completed, we are confident in our expectation that we will exceed $92 million in revenue for the first quarter of 2018."

AmnioFix® Injectable Granted Regenerative Medicine


Advanced Therapy (RMAT) Designation by the FDA for the Treatment of Osteoarthritis of the Knee MARIETTA, Ga., March 9, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that the U.S. Food and Drug Administration (FDA) has granted MiMedx's micronized amniotic tissue, AmnioFix® Injectable, the Regenerative Medicine Advanced Therapy (RMAT) designation for use in the treatment of Osteoarthritis (OA) of the knee. In its letter to the Company, the FDA confirmed its determination that MiMedx Allogeneic Micronized Dehydrated Human Amnion/Chorion Membrane (micronized dHACM) for the treatment of OA of the knee meets the criteria for RMAT designation. The FDA further stated that MiMedxhas provided clinical information to demonstrate preliminary clinical evidence to indicate that the drug has the potential to address unmet medical needs for this condition.

Atlanta startup creates pill-dispensing device to prevent addiction


Georgia has one of the highest numbers of prescription opioid overdose deaths in the U.S., so it’s only natural that local businesses would seek a solution. Intent Solutions, a startup in Atlanta, has created a pill bottle called Take As Directed (tad). The device dispenses a set dosage of a medication only when a patient is supposed to take it, and it has a biometric fingerprint scanner so no one but the patient can access the medication. Take As Directed also streams all that data to the cloud, so clinicians and researchers can learn more about how people take medicine.

Clearside Biomedical Announces Positive Topline Results


Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-T Primary Endpoint Achieved – Statistically Significant Improvement in Proportion of Patients Gaining 15 or More Letters in Visual Acuity All Key Secondary Endpoints Achieved Clearside to Host Conference Call Today at 8:30 AM Eastern Time ALPHARETTA, Ga., March 05, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced positive topline results from its pivotal Phase 3 clinical trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis. Suprachoroidal CLS-TA is Clearside’s proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye via the suprachoroidal space, or SCS™, which is the space located between the choroid and the outer protective layer of the eye known as the sclera.

The Biobased Economy Is Reaching a Tipping Point


By Brent Erickson, executive vice-president; Head, Industrial & Environmental Section, Biotechnology Innovation Organization Special to The Digest This week, I’ll be addressing the Advanced Biofuels Leadership Conference. I’d like to thank Jim Lane for giving me that opportunity again this year. I appreciate it, because BIO is the only trade association that advocates for the diverse policies that support the entire biobased economy – the full value chain of technologies and infrastructure to convert renewable, low-carbon, low-cost feedstocks and waste streams into value-added consumer products, including renewable chemicals and biofuels.

Georgia Bio Elects First Female Chair


ATLANTA, GA (February 23, 2018) – This month, UCB’s Vice President for U.S. Corporate Affairs, Patricia A. Fritz, was elected chair of Georgia Bio’s Board of Directors for the 2018-2019 term. Dr. Lee Herron, Vice President for Venture Development at the Georgia Research Alliance will serve as Vice Chair. Ms. Fritz succeeds Dr. Jay Yadav, Founder and CEO of MiRus, who will remain on the Georgia Bio Board and Executive Committee as Immediate Past Chair. “We are thrilled to welcome Patty as our board chair. As a long-time board member she demonstrates the commitment that our state’s top leaders have in supporting the growth and innovation in Georgia’s life science ecosystem,” said Russell Allen, Georgia Bio president and CEO. Allen continued, “As Georgia’s life sciences sector becomes more recognized for its global leadership, it is important that we show that the community also values gender diversity, fosters leadership opportunities for women and promotes women to its highest offices. Electing Patty is one way we as an organization are achieving that.”

American Cancer Society, Global Center for Medical Innovation to raise $5 million for research


The Atlanta-based American Cancer Society and Global Center (GCMI)for Medical Innovation partnered to raise $5 million to bring research from the lab to the clinic more quickly. GCMI will unite members of the medical device community like universities, research centers, hospitals, clinicians and investors to speed up technologies that result from ACS-funded research. The goal is to reduce the time and cost of bringing new ideas to market. The partners will pick three to five projects to focus on each year. “This partnership provides further testimony to the health of the med-tech development ecosystem in Atlanta,” said GCMI CEO Tiffany Wilson in a statement. “Our collective resources should enable us to de-risk innovation bringing new products to market capable of improving cancer treatment. Ultimately this should translate into reduced ‘time-to-cures’ and lower cost of development and care.”

BIO Unveils Refreshed Advocate Toolkit


This past March, BIO launched, an interactive web tool designed to help policymakers, members of the media and the broader public access the best facts surrounding drug costs, spending and value. By featuring a series of commonly asked questions, as well as research and reading materials, BIO created a one-stop shop for answers to some of the most hotly debated questions regarding the important roles of biopharmaceutical innovation and prescription medicines in our nation’s health care system.

Previous  |  1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15  |  16  |  17  |  18  |  19  |  20  |  21  |  22  |  23  |  24  |  25  |  Next